We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Q4 Scorecard and Analyst Reports for AT&T, Biogen & Qualcomm
Read MoreHide Full Article
Friday, January 27 2017
The Zacks Research Daily features the best output of our research team every day. In today’s write-up, we are featuring analyst reports on 16 major stocks, including reports on AT&T (T - Free Report) , Biogen (BIIB - Free Report) and Qualcomm (QCOM - Free Report) . These stock research reports have been hand-picked from the 70 or so reports published by our analyst team today. You can see all of today’s research reports here >>
In addition to the stock research reports, we are also giving you a real-time scorecard of the ongoing Q4 earnings season. We take pride in closely monitoring each and every earnings report and presenting our analysis of emerging trends in the weekly Earnings Trends and Earnings Preview reports. Our latest Earnings Trends report is: 3 Takeaways from the Q4 Earnings Season
Q4 Earnings Scorecard: We are one-third into the Q4 earnings season, with results from 170 S&P 500 members, or 33.9% of the index's total membership, already out. More than 400 companies are on the docket to report quarterly results next week, including 106 S&P 500 members. By the end of next week, we will have seen Q4 results from 55% of S&P 500 members.
Total earnings for the 170 index members that have reported results already are up +6% on +3.1% higher revenues, with 64.1% beating EPS estimates and 54.7% beating revenue estimates. This is better earnings and revenue growth performance than we have seen from this group of 170 S&P 500 members in other recent periods, even after adjusting for the strong growth from the Finance sector. The proportion of companies beating EPS and revenue estimates, however, is tracking moderately below other recent periods.
Looking at Q4 as a whole, combining the actual results from the 170 index members with estimates from the still-to-come 330 companies, total earnings are expected to be up +5.2% from the same period last year on +4% higher revenues. This is the best earnings and revenue growth pace in the last 8 quarters. Importantly, estimates for the current period (2017 Q1) are holding up fairly well; they are coming down, but not at the pace as would typically expected. All of this should help add to confidence in market expectations for the current and following quarters when growth is expected to notably ramp up.
AT&T shares have surged +14.4% over the three months, outperforming the Zacks Wireless industry and competitor Verizon, which have gained +10.9% and +1.7% over the same period. While Q4 results were mixed (modestly missed on the top-line even as it matched bottom-line expectations), trends in the wireless business pointed towards stabilization in terms of the subscriber base and the churn rate. Market participants also appear to be satisfied with AT&T's strategic moves like the DirectTV purchase and the pending Time Warner deal even as Verizon's path seems muddled. That said, there is shortage of issues facing the company, like a saturated wireless market where spectrum crunch is a big issue, persistent losses in access lines, and stringent regulatory mandates. (You can read the full research report on AT&T here >>)
Biogen shares initially gained from the post-election rally, but have since underperformed the broader pharma space as the macro issues plaguing the space still continue. Biogen reported mixed fourth-quarter results, beating on earnings but missing on sales. These issues notwithstanding, the analyst likes the stock’s strong position in the multiple sclerosis market primarily due to a wide range of products. Cost cutting efforts and MS franchise sales should continue to drive growth. Moreover, the upcoming spin-off of the hemophilia business will allow Biogen to focus on the neurology segment, its key area of expertise. (You can read the full research report on Biogen here >>)
Qualcomm shares have suffered lately, with the stock losing -21% over the last three months vs. the -3.6% decline for the Zacks Wireless Equipment industry. Qualcomm posted mixed quarterly results recently, with the bottom line meeting expectations and the top line falling short. But the Zacks analyst likes the company’s active involvement in the production of chipsets for the 5G standard. Also, Qualcomm is widening its presence in adjacent opportunities, including automotive, networking, and mobile computing strategies. However, aggressive competition in the mobile phone chipset market, stringent regulatory norms and anti-competitive charges are some of the major headwinds faced by the company. (You can read the full research report on Qualcomm here >>)
Other noteworthy reports we are featuring today include Facebook , Comcast (CMCSA - Free Report) and Royal Caribbean (RCL - Free Report) .
Today's Private Buys & Sells from Zacks Research While we share the above news with the public, our sensitive recommendations are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>
Sheraz Mian
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here >>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Q4 Scorecard and Analyst Reports for AT&T, Biogen & Qualcomm
Friday, January 27 2017
The Zacks Research Daily features the best output of our research team every day. In today’s write-up, we are featuring analyst reports on 16 major stocks, including reports on AT&T (T - Free Report) , Biogen (BIIB - Free Report) and Qualcomm (QCOM - Free Report) . These stock research reports have been hand-picked from the 70 or so reports published by our analyst team today. You can see all of today’s research reports here >>
In addition to the stock research reports, we are also giving you a real-time scorecard of the ongoing Q4 earnings season. We take pride in closely monitoring each and every earnings report and presenting our analysis of emerging trends in the weekly Earnings Trends and Earnings Preview reports. Our latest Earnings Trends report is: 3 Takeaways from the Q4 Earnings Season
Q4 Earnings Scorecard: We are one-third into the Q4 earnings season, with results from 170 S&P 500 members, or 33.9% of the index's total membership, already out. More than 400 companies are on the docket to report quarterly results next week, including 106 S&P 500 members. By the end of next week, we will have seen Q4 results from 55% of S&P 500 members.
Total earnings for the 170 index members that have reported results already are up +6% on +3.1% higher revenues, with 64.1% beating EPS estimates and 54.7% beating revenue estimates. This is better earnings and revenue growth performance than we have seen from this group of 170 S&P 500 members in other recent periods, even after adjusting for the strong growth from the Finance sector. The proportion of companies beating EPS and revenue estimates, however, is tracking moderately below other recent periods.
Looking at Q4 as a whole, combining the actual results from the 170 index members with estimates from the still-to-come 330 companies, total earnings are expected to be up +5.2% from the same period last year on +4% higher revenues. This is the best earnings and revenue growth pace in the last 8 quarters. Importantly, estimates for the current period (2017 Q1) are holding up fairly well; they are coming down, but not at the pace as would typically expected. All of this should help add to confidence in market expectations for the current and following quarters when growth is expected to notably ramp up.
AT&T shares have surged +14.4% over the three months, outperforming the Zacks Wireless industry and competitor Verizon, which have gained +10.9% and +1.7% over the same period. While Q4 results were mixed (modestly missed on the top-line even as it matched bottom-line expectations), trends in the wireless business pointed towards stabilization in terms of the subscriber base and the churn rate. Market participants also appear to be satisfied with AT&T's strategic moves like the DirectTV purchase and the pending Time Warner deal even as Verizon's path seems muddled. That said, there is shortage of issues facing the company, like a saturated wireless market where spectrum crunch is a big issue, persistent losses in access lines, and stringent regulatory mandates. (You can read the full research report on AT&T here >>)
Biogen shares initially gained from the post-election rally, but have since underperformed the broader pharma space as the macro issues plaguing the space still continue. Biogen reported mixed fourth-quarter results, beating on earnings but missing on sales. These issues notwithstanding, the analyst likes the stock’s strong position in the multiple sclerosis market primarily due to a wide range of products. Cost cutting efforts and MS franchise sales should continue to drive growth. Moreover, the upcoming spin-off of the hemophilia business will allow Biogen to focus on the neurology segment, its key area of expertise. (You can read the full research report on Biogen here >>)
Qualcomm shares have suffered lately, with the stock losing -21% over the last three months vs. the -3.6% decline for the Zacks Wireless Equipment industry. Qualcomm posted mixed quarterly results recently, with the bottom line meeting expectations and the top line falling short. But the Zacks analyst likes the company’s active involvement in the production of chipsets for the 5G standard. Also, Qualcomm is widening its presence in adjacent opportunities, including automotive, networking, and mobile computing strategies. However, aggressive competition in the mobile phone chipset market, stringent regulatory norms and anti-competitive charges are some of the major headwinds faced by the company. (You can read the full research report on Qualcomm here >>)
Other noteworthy reports we are featuring today include Facebook , Comcast (CMCSA - Free Report) and Royal Caribbean (RCL - Free Report) .
Today's Private Buys & Sells from Zacks Research
While we share the above news with the public, our sensitive recommendations are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>
Sheraz Mian
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here >>>